Acquisition of CAR-NK Assets to Bolster Cancer Therapy Portfolio
TC BioPharm (TCBP), a leading biotechnology company specializing in allogeneic gamma-delta T cell therapies, revealed its latest move to enhance its therapeutic platform through the acquisition of proprietary CAR-NK assets. The company’s non-binding letter of intent signifies a strategic shift towards leveraging natural killer (NK) cells in the treatment of solid tumors and other indications.
The target acquisition encompasses two allogeneic CAR-NK therapeutics, specifically designed for combating solid tumors, including CD-70 and HER2 CAR-NK technologies. TCBP anticipates significant synergies from integrating these assets with its existing TCB-008 therapy, paving the way for enhanced treatment outcomes and expanded clinical trial efforts.
CEO Bryan Kobel highlighted the strategic significance of the proposed asset acquisition, emphasizing its potential to position TCBP as a leader in cell therapy. By combining complementary technologies and leveraging manufacturing expertise, TCBP aims to accelerate the development of novel cell therapies while maximizing future shareholder value. Pending the execution of definitive agreements and regulatory approvals, this strategic move underscores TCBP’s commitment to advancing innovative treatments for cancer and other diseases.
Read original press release: here
You might like this article:Candel Therapeutics Reports Encouraging Survival Data for CAN-2409 in Pancreatic Cancer
